Skandinaviska Enskilda Banken AB publ Cuts Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Skandinaviska Enskilda Banken AB publ trimmed its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 16.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 66,455 shares of the company’s stock after selling 13,348 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in Moderna were worth $2,616,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently bought and sold shares of the company. State Street Corp raised its stake in shares of Moderna by 12.1% during the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company’s stock worth $1,125,899,000 after purchasing an additional 1,823,276 shares during the period. Geode Capital Management LLC raised its stake in shares of Moderna by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock worth $470,670,000 after purchasing an additional 178,115 shares during the period. Wellington Management Group LLP raised its stake in shares of Moderna by 21.0% during the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock worth $349,166,000 after purchasing an additional 906,114 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Moderna by 0.5% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company’s stock worth $260,023,000 after purchasing an additional 19,819 shares during the period. Finally, The Manufacturers Life Insurance Company raised its stake in Moderna by 6.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company’s stock valued at $205,431,000 after acquiring an additional 178,939 shares during the period. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Price Performance

Shares of NASDAQ MRNA opened at $34.62 on Monday. Moderna, Inc. has a one year low of $29.25 and a one year high of $170.47. The firm’s 50 day simple moving average is $35.94 and its two-hundred day simple moving average is $47.15. The stock has a market capitalization of $13.36 billion, a P/E ratio of -3.73 and a beta of 1.86.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Piper Sandler restated an “overweight” rating and issued a $69.00 price objective (down from $115.00) on shares of Moderna in a research note on Monday, November 18th. Royal Bank of Canada restated a “sector perform” rating and issued a $40.00 price objective on shares of Moderna in a research note on Tuesday, February 18th. JPMorgan Chase & Co. set a $45.00 price objective on Moderna in a research note on Friday, February 14th. Bank of America lowered their price objective on Moderna from $41.00 to $34.00 and set an “underperform” rating on the stock in a research note on Tuesday, February 11th. Finally, Leerink Partners decreased their price target on Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a research report on Thursday, January 16th. Four analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $59.60.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.